Indeus

Indeus Inc. is a Tokyo-based biotechnology company specializing in the discovery of innovative small molecule drugs using a proprietary multidisciplinary platform. The company's core technology, i-MDD (Indeus-Multidisciplinary Drug Discovery), combines in silico screening, structural biology, and medicinal chemistry to design high-precision covalent inhibitors and other small molecules. Indeus focuses on addressing "undruggable" targets, particularly in the fields of oncology and inflammatory diseases. Led by a team with extensive experience in kinase inhibitor development, the company collaborates with academic and industry partners to advance its internal pipeline. Indeus has successfully secured venture capital funding to support its mission of delivering transformative medicines for patients with limited treatment options. The company represents a growing wave of Japanese startups leveraging advanced computational tools for drug design.